| Heading: |
Prostate Cancer: Hormone Treatments |
| Question ID: |
1818955 |
| UIN: |
64681 |
| House: |
Commons |
| Date tabled: |
2025-07-02 |
| Asking Member ID: |
5339 |
| Asking Member display name: |
Danny Beales
|
| Asking Member handle: |
DannyBeales
|
| Asking Member Twitter reference: |
@DannyBeales
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, with reference to the randomised control trial study report entitled Cost utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long term hormone therapy in newly diagnosed |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-07-09 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
NHS England considered abiraterone as an off-label treatment for hormone sensitive, non-metastatic prostate cancer through its clinical policy development process in 2024/25. Through this process, NHS England confirmed that there was sufficient supporting... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |